Header

UZH-Logo

Maintenance Infos

Phenylketonuria and BH4 deficiencies


Phenylketonuria and BH4 deficiencies. Edited by: Blau, N; Burton, B K; Thöny, B; van Spronsen, F J; Waisbren, S (2010). Bremen: UNI-MED Verlag AG.

Abstract

Thanks to newborn screening and early dietary therapy, individuals with PKU no longer experience intellectual disability (mental retardation). Nevertheless, many do not achieve their full potential. The establishment of uniform guidelines and improved management for PKU can lead to optimal outcomes in this metabolic disorder. Two new approaches are currently available for the treatment of PKU in some patients:- The use of tetrahydrobiopterin (BH4; sapropterin) in individuals with PKU with certain mutations of the phenylalanine hydroxylase gene.- Supplementation with large neutral amino acids (LNAA) other than phenylalanine.Further approaches, such as recombinant phenylalanine ammonia lyase (PAL), which degrades phenylalanine, and gene therapy, using viral or non-viral vectors to correct murine PKU, are at the experimental stage.In this textbook past, present, and future efforts related to PKU and BH4 deficiencies are discussed. The reviews and scientific contributions in this book provide professionals, the patients and their families to understand PKU within a biochemical, neurological and psychosocial context.

Abstract

Thanks to newborn screening and early dietary therapy, individuals with PKU no longer experience intellectual disability (mental retardation). Nevertheless, many do not achieve their full potential. The establishment of uniform guidelines and improved management for PKU can lead to optimal outcomes in this metabolic disorder. Two new approaches are currently available for the treatment of PKU in some patients:- The use of tetrahydrobiopterin (BH4; sapropterin) in individuals with PKU with certain mutations of the phenylalanine hydroxylase gene.- Supplementation with large neutral amino acids (LNAA) other than phenylalanine.Further approaches, such as recombinant phenylalanine ammonia lyase (PAL), which degrades phenylalanine, and gene therapy, using viral or non-viral vectors to correct murine PKU, are at the experimental stage.In this textbook past, present, and future efforts related to PKU and BH4 deficiencies are discussed. The reviews and scientific contributions in this book provide professionals, the patients and their families to understand PKU within a biochemical, neurological and psychosocial context.

Statistics

Altmetrics

Additional indexing

Item Type:Edited Scientific Work
Communities & Collections:04 Faculty of Medicine > University Children's Hospital Zurich > Medical Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2010
Deposited On:06 Jan 2011 13:57
Last Modified:11 Aug 2017 20:23
Publisher:UNI-MED Verlag AG
Number of Pages:77
ISBN:978-3-8374-1238-3
Related URLs:http://www.uni-med.de/kinderheilkunde_phenylketonuria_and_bh4_deficiencies,pid,475,rid,25,produktdetail.html (Publisher)

Download

Full text not available from this repository.